Researchers in low- and middle-income countries are developing their own IP, scaling up local manufacturing, and looking for biomarkers — all in the hope of bringing costs down and getting therapies to people who need them.
We are living in the age of biology, where new research is translated daily into potential treatments for deadly diseases. Researchers are conducting thousands of clinical trials to assess the efficacy of these first-in-human therapeutics, but alongside excitement, innovation brings costs. These costs are paid by healthcare providers and patients, leaving many blockbuster treatments, from gene therapy and chimeric antigen receptor (CAR)-T cells to immune checkpoint inhibitors, out of reach for most of the world.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Author information
Authors and Affiliations
London, UK
Ben Johnson
About this article
Cite this article
Johnson, B. Reducing the costs of blockbuster gene and cell therapies in the Global South.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-023-02049-3
Download citation
Published: 11 January 2024
DOI: https://doi.org/10.1038/s41587-023-02049-3
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-02049-3
